指南与共识头痛与眩晕

成人偏头痛预防性药物治疗实践指南推荐

Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society.
指南 / 共识 · Neurology · 2026-08-31

本实践指南由美国神经病学学会指南小组委员会与美国头痛学会联合制定,基于截至2024年6月6日的系统综述,采用2017版AAN临床实践指南制定手册流程,通过多学科小组提出关于成人偏头痛预防性药物治疗的更新推荐,涵盖启动时机、药物选择、特殊人群考量及疗效评估与停药等。

要点

  • 指南推荐基于系统综述与结构化理由,明确何时启动偏头痛预防性药物治疗。
  • 针对纤维肌痛、肥胖、高血压、老年人、妊娠哺乳期及药物过度使用等特殊情况提供决策推荐。
  • 推荐涉及疗效与不良反应评估以及预防性药物停药的考量。

核心结论

  • 指南提供了成人偏头痛预防性药物治疗的更新循证推荐,涵盖启动决策、药物选择及特殊人群管理。

研究设计与样本

  • 多学科小组依据2017版AAN临床实践指南制定手册流程,基于截至2024年6月6日的系统综述制定实践推荐。

关键数值与推荐

  • 推荐涉及如何决定何时启动偏头痛预防性药物以及如何选择起始预防性药物。
  • 推荐涉及纤维肌痛、肥胖或高血压患者、老年人、妊娠和哺乳期、性别相关因素及药物过度使用患者的药物选择决策。
  • 推荐涉及治疗疗效评估、不良反应评估以及停用偏头痛预防性药物。

临床怎么用

  • 临床可根据指南推荐决定偏头痛预防性药物的启动时机与药物选择,并针对特殊人群和药物过度使用情况个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This practice guideline provides updated evidence-based recommendations regarding the use of pharmacologic migraine prevention in adults. A multidisciplinary panel conducted a systematic review and developed practice recommendations following the process outlined in the 2017 edition of the American Academy of Neurology Clinical Practice Guideline Process Manual. The systematic review includes studies published through June 6, 2024, and is available in a companion publication. Recommendations are supported by structured rationales that integrate evidence from the systematic review, related evidence, principles of care, and inferences from evidence. Recommendations are provided on how to decide when it is appropriate to start a pharmacologic migraine preventive medication and how to decide which migraine preventive medication to start. Recommendations address decision making on appropriate choices of migraine preventive medications in specific situations and populations, including patients with fibromyalgia, obesity, or hypertension; considerations for older adults; treatment during pregnancy and lactation; sex-related factors in choosing medications; and treatment for patients with medication overuse. Recommendations on assessment of treatment efficacy, adverse effects, and discontinuing migraine preventive medications are provided.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Potrebic S, Tanveer S, Becker WJ, et al. Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society. Neurology. 2026. PMID: 42673560. doi:10.1212/WNL.0000000000214881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。